Company profile
Curaleaf Holdings, Inc.
OTC: CURLF · Healthcare · Drug Manufacturers - Specialty & Generic
#138 of 1,417 Healthcare companies by revenue35th-percentile growth
EA Score
49DFH 65DQ 16GM 54SS 73
v0.1 · 65/100 weight · provisional
↑ workforce scale, growth stability · ↓ filing timeliness, disclosure history
Methodology →Revenue TTM
$1.3B
Rev growth YoY (TTM)
-0.6%
Net income (FY)
-$231.1M
Employees
5,575
as of 2026-08-08
Market cap
$2.5B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3B$1.3B2025
Net income-$231.1M-$231.1M2025
Operating income$25.4M$25.4M2025
Total assets$2.8B$2.8B2025
Liabilities$2.0B$2.0B2025
Equity$756.4M$756.4M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Retail73%
Wholesale Revenue26%
Management Fee Income1%
By geography
Domestic100%
The read
What is Curaleaf Holdings, Inc.’s revenue?
Curaleaf Holdings, Inc. booked $1.3B in FY2025 revenue, contracting 5.6% year over year — slower than 65% of Healthcare companies we track, at a -18.2% net margin.
Peers · Healthcare
Phibro Animal Health Corporation76B+Progyny, Inc.71BTempus AI, Inc.59CIndivior Pharmaceuticals Inc67BBio-Techne Corporation85AExtendicare Inc.79B+Neighbors
Fairfield →Key facts
CEOBoris Alexis Jordan
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersStamford, CT
ExchangeOTC: CURLF
Employees5,575
IPO date2018-10-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.